FHTX (Foghorn Therapeutics) Tariff Resilience Score: 6/10 (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
67 GF Score
Price $6.69
GF Value $5.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Foghorn Therapeutics Tariff Resilience Score?

Foghorn Therapeutics FHTX -2.19% 67 Tariff Resilience Score is 6 as of Aug. 26, 2026. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,361 Biotechnology companies, Foghorn Therapeutics ranks better than 76.05% on this metric.

Foghorn Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Foghorn Therapeutics has Biotech firm with some exposure to tariffs on imported research materials. However, the impact is limited due to the specialized nature of its products and potential for alternative sourcing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Foghorn Therapeutics might have Average Resilient.

Foghorn Therapeutics  (NAS:FHTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Foghorn Therapeutics Tariff Resilience Score Related Terms

FHTX vs NWBO, FATE, IMRX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Foghorn Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foghorn Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's Tariff Resilience Score falls into.


FHTX
67GF Score
Foghorn Therapeutics Inc FHTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Foghorn Therapeutics (FHTX) has a Tariff Resilience Score of 6 as of Aug. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Foghorn Therapeutics ranks #326 out of 1361 companies in the Biotechnology industry, placing it in the top 24%.
Is Foghorn Therapeutics' Tariff Resilience Score too high?
Foghorn Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Foghorn Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Foghorn Therapeutics ranks #326 out of 1361 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Tariff Resilience Score compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #326 out of 1361 companies for Tariff Resilience Score. This places Foghorn Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Foghorn Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,361 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foghorn Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.69 — trading 25.8% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Tariff Resilience Score is 6 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued. The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32. GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.

Key valuation signals for FHTX:

  • Tariff Resilience Score: 6
  • GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
  • GF Score™: 67/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#326 of 1361)

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score

Get the complete analysis for FHTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$5.32
GF Value